Printer Friendly

MAGAININ PHARMACEUTICALS ANNOUNCES HIRING OF DR. TAFFY WILLIAMS, VICE PRESIDENT, RESEARCH

 MAGAININ PHARMACEUTICALS ANNOUNCES HIRING OF
 DR. TAFFY WILLIAMS, VICE PRESIDENT, RESEARCH
 PLYMOUTH MEETING, Pa., March 18 /PRNewswire/ -- Jay Moorin, president and chief executive officer of Magainin Pharmaceuticals Inc. (NASDAQ: MAGN) today announced the appointment of Dr. Taffy Williams as vice president of research.
 Williams joins Magainin Pharmaceuticals from the Naval Medical Research Institute, Bethesda, Md., where he served as director of their Septic Shock Research Program. He also served on the institute's scientific advisory board.
 Williams received his bachelor of science in chemistry from the University of Notre Dame, his Ph.D. in biochemistry from the University of South Carolina and was a postdoctoral fellow at the University of Michigan. He was the recipient of the Civilian Civil Service Special Achievement Award in 1986, and has been cited by the Naval Medical Research Institute for producing significant scientific publications.
 Moorin stated, "Williams brings outstanding scientific credentials to Magainin in areas of chemistry and biology. His experience will allow us to explore unique research opportunities and could accelerate the generation of new therapeutic candidates for clinical trials."
 Williams will report to Leonard Jacob, M.D., Ph.D., executive president of research and development.
 Magainin Pharmaceuticals Inc., is a biopharmaceutical company dedicated to the research, development and commercialization of novel host-defense pharmaceuticals for treatment of infections, wounds and cancer.
 /delval/
 -0- 3/18/92
 /CONTACT: Jay Moorin, president and chief executive officer of Magainin Pharmaceuticals, 215-941-4020/
 (MAGN) CO: Magainin Pharmaceuticals Inc. ST: Pennsylvania IN: MTC SU: PER


JS-CC -- PH026 -- 9294 03/18/92 13:56 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 18, 1992
Words:254
Previous Article:VERSAR ANNOUNCES STRATEGIC RESTRUCTURING OF VERSAR LABORATORIES TO IMPROVE PROFITABILITY
Next Article:SUNBELT NURSERY GROUP REPORTS RESULTS FOR YEAR ENDED JANUARY 31, 1992
Topics:


Related Articles
MAGAININ PHARMACEUTICALS ANNOUNCES RESIGNATION
MAGAININ PHARMACEUTICALS ANNOUNCES FORMATION OF NEW INSTITUTE TO BE DIRECTED BY DR. MICHAEL ZASLOFF
MAGAININ PHARMACEUTICALS AND SANDOZ ANNOUNCE STRATEGIC ALLIANCE IN CANCER
MAGAININ PHARMACEUTICALS AND SANDOZ ANNOUNCE STRATEGIC ALLIANCE IN CANCER
SCIENTISTS ISOLATE NEW ANTIBIOTICS FROM SHARK
MAGAININ PHARMACEUTICALS ANNOUNCES RESIGNATION OF LEONARD S. JACOB AND PROMOTION OF PAUL LITKA
MAGAININ PHARMACEUTICALS APPOINTS THOMAS BIGGER AS SENIOR VICE PRESIDENT OF BUSINESS DEVELOPMENT, MARKETING AND SALES
MAGAININ PHARMACEUTICALS NAMES JAY MOORIN CHAIRMAN, PRESIDENT AND CEO AND MICHAEL ZASLOFF AS VICE CHAIRMAN
InKine Pharmaceutical - Formerly Panax Pharmaceutical Completes $17 Million Private Financing
SunPharm Elects Jay Moorin to Newly Created Seat on Board of Directors

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters